This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Incyte's CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

Stocks in this article: INCY

Incyte Corporation (INCY)

Morgan Stanley Healthcare Conference Call

September 12, 2012 10:55 am ET

Executives

Paul A. Friedman – President and Chief Executive Officer

David C. Hastings – Executive Vice President, Chief Financial Officer

Analysts

David Friedman – Morgan Stanley & Co. LLC

Presentation

David Friedman – Morgan Stanley & Co. LLC

All right. I think we will get started here and thanks everyone for joining us. I’m Dave Friedman, one of the Biotech Analyst. And in terms of personal and research disclosures, you can look at morganstanley.com/disclosure. And I’m joined happily up here by the team from Incyte on the far side Dave Hastings, Chief Financial Officer and then on the near side Paul Friedman, and the relation President and CEO.

And we’d look for this to be as interactive as possible, so anyone should please feel free to raise your hand and shout out, and we’ll make sure we can get your questions asked. So thank you both again for joining us and I think we can just jump right in. You guys relatively recently have had a drug approved for a rare blood diseases, and so maybe you can just talk about the drug, the approval and how the commercial roll out has gone so far.

Paul A. Friedman

Sure. So the drug is JAKAFI, generic name ruxolitinib. It is an inhibitor of two kinases, in a family of kinases known as Janus associated kinase. They are JAK1, JAK2, JAK3 and Tyk2, were all related and a family of enzymes. Our compound inhibits JAK1, and JAK2, but not JAK3, and inhibits Tyk2 to a significantly less degree than JAK1 and JAK2.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs